In this systematic review, we aim to explore and aggregate the latest literature findings on the cardiovascular effects of GLP-1 agonists and dual GLP-1/GIP agonists in T2DM with or without pre-existing cardiovascular risk factors. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.